Expense

Kerr Mines and Star Royalties Announce US$18 Million Project Financing for Restart of the Copperstone Gold Mine

Retrieved on: 
Thursday, November 12, 2020

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Kerr Mines Inc. (TSX: KER, OTC: KERMF) (Kerr or the Company) and Star Royalties Ltd. (Star Royalties) are very pleased to jointly announce the execution of a definitive US$18,000,000 gold purchase and sale agreement (Streaming Agreement) to finance the restart of underground operations and gold production at the Copperstone Gold Mine (Copperstone) in Arizona, USA.

Key Points: 
  • TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Kerr Mines Inc. (TSX: KER, OTC: KERMF) (Kerr or the Company) and Star Royalties Ltd. (Star Royalties) are very pleased to jointly announce the execution of a definitive US$18,000,000 gold purchase and sale agreement (Streaming Agreement) to finance the restart of underground operations and gold production at the Copperstone Gold Mine (Copperstone) in Arizona, USA.
  • Giulio T. Bonifacio, Chief Executive Officer of Kerr, stated: This Streaming Agreement provides the required project financing to restart gold production at our Copperstone Gold Mine, which is targeted for Q4-2021.
  • With the extensive project evaluation undertaken by Star Royalties, we believe this streaming transaction further validates the value we have identified at Copperstone by way of our recent optimization efforts.
  • Alex Pernin, Chief Executive Officer of Star Royalties, commented: We are proud to announce our partnership transaction with Kerr to advance the restart of Copperstone.

DGAP-News: amcure and Hinova Pharmaceuticals enter into an exclusive license agreement for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region

Retrieved on: 
Thursday, November 12, 2020

amcure and Hinova Pharmaceuticals enter into an exclusive license agreement for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region

Key Points: 
  • amcure and Hinova Pharmaceuticals enter into an exclusive license agreement for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region
    The issuer is solely responsible for the content of this announcement.
  • Under the terms of the agreement, Hinova will develop, manufacture and commercialize AMC303 for the Greater China market with an initial focus on esophageal metastatic squamous cancer.
  • amcure retains all rights to AMC303 outside of the Greater China region.
  • As part of the agreement, amcure will receive an upfront payment, plus development and commercial milestone payments as well as royalties on net sales.

XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement

Retrieved on: 
Wednesday, November 11, 2020

Todays announcement marks the first asset that the XOMA team acquired under our royalty and milestone aggregator business model to achieve a clinical milestone.

Key Points: 
  • Todays announcement marks the first asset that the XOMA team acquired under our royalty and milestone aggregator business model to achieve a clinical milestone.
  • XOMA has built a significant portfolio of products that are licensed to and being developed by other biotech and pharmaceutical companies.
  • The Companys royalty-aggregator business model includes acquiring additional milestone and royalty rights associated with drug development programs with third-party funding.
  • As of the date of this press release, all assets in XOMAs milestone and royalty portfolio are investigational compounds.

New AppZen Expense Reimbursement Survey Reveals Impact of COVID and Remote Work on Employees

Retrieved on: 
Wednesday, November 11, 2020

New data released today by AppZen , the worlds leading AI solution for modern finance teams, reveals how the pandemic and remote work have impacted company expense reports.

Key Points: 
  • New data released today by AppZen , the worlds leading AI solution for modern finance teams, reveals how the pandemic and remote work have impacted company expense reports.
  • Surveying 1,000 workers of companies with at least 250 employees, the data provides insight into how companies have adapted new expense policies and how those changes have impacted employees.
  • 75 percent of employees submitted work from home expenses during the pandemic versus 69 percent of employees who submitted expenses pre-COVID.
  • 51 percent of employees said their employer updated their expense policy due to COVID.

Royalty Pharma Reports Third Quarter 2020 Results

Retrieved on: 
Tuesday, November 10, 2020

Drivers of royalty receipts in the third quarter of 2020 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of royalty receipts in the third quarter of 2020 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma will receive a royalty of 0.4% on Nurtec ODT, a royalty of up to 3% on zavegepant and success-based milestone payments based on zavegepant regulatory approvals.
  • Royalty Pharma has updated guidance for full-year 2020 as follows:
    Royalty Pharma also expects that payments for operating and professional costs will be approximately 10% of Adjusted Cash Receipts in 2020.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss this financial results release at 8:00 a.m., Eastern Time on November 11, 2020.

Periscope Invests in MobiChord

Retrieved on: 
Tuesday, November 10, 2020

CHICAGO, Nov. 10, 2020 /PRNewswire/ -- Periscope Equity ("Periscope") today announced its investment in MobiChord , Inc. ("MobiChord" or the "Company"), an innovative Technology Expense Management ("TEM") software platform and ServiceNow Elite Partner.

Key Points: 
  • CHICAGO, Nov. 10, 2020 /PRNewswire/ -- Periscope Equity ("Periscope") today announced its investment in MobiChord , Inc. ("MobiChord" or the "Company"), an innovative Technology Expense Management ("TEM") software platform and ServiceNow Elite Partner.
  • Founded in 2013, MobiChord is a Salt Lake City, Utah-based TEM software platform built natively on the ServiceNow platform.
  • MobiChord quickly established itself as a disruptor in the TEM market pushing the boundaries of traditional telecom expense management.
  • "MobiChord is a truly unique player in the TEM market," said Eric Hinkle, Principal at Periscope Equity.

Payroll Planning Needed to Adapt to Federal Programs, Uncover Opportunities for Savings

Retrieved on: 
Tuesday, November 10, 2020

Payroll leaders should be focusing now on being better prepared for sudden operating changes by updating and formalizing business continuity plans for both internal and outsourced operations.

Key Points: 
  • Payroll leaders should be focusing now on being better prepared for sudden operating changes by updating and formalizing business continuity plans for both internal and outsourced operations.
  • The current pandemic crisis puts payroll policy, strategy and operations in the spotlight, Fernandez said.
  • Organizations also must consider how unemployment and other federal programs play into the decision to retain or rehire employees.
  • Payroll operations need to comply with government paycheck protection programs and eligibility for business loans and incentives, Fernandez said.

Inspire Medical Systems, Inc. Announces Full Integration of Inspire Therapy into German DRG Reimbursement System to Begin in 2021

Retrieved on: 
Monday, November 9, 2020

Germanys Institute for the Hospital Remuneration System (InEK) recently published the list of treatment methods, including Inspire therapy, to be included in the regular DRG catalog.

Key Points: 
  • Germanys Institute for the Hospital Remuneration System (InEK) recently published the list of treatment methods, including Inspire therapy, to be included in the regular DRG catalog.
  • Since January 2016, Germanys reimbursement for the Inspire procedure has been provided through the NUB process for new diagnostic and treatment procedures.
  • The NUB process requires hospitals to submit applications annually to obtain approval to perform the Inspire procedure.
  • While Inspire therapy has received the top NUB1 rating for each of the last five years, this remains an interim step in establishing formal reimbursement in Germany.

October Brings Boost in Small Business Hiring

Retrieved on: 
Friday, November 6, 2020

Historically, small business hiring decreases in October, with this months data deviating from the norm as continued reopening and engagement among consumers drove growth.

Key Points: 
  • Historically, small business hiring decreases in October, with this months data deviating from the norm as continued reopening and engagement among consumers drove growth.
  • The CBIZ SBEI tracks payroll and hiring trends for over 3,500 companies that have 300 or fewer employees, providing broad insight into small business trends.
  • Positive trends in small business employment were echoed in the ADP and Moodys employment report, as private-sector jobs rose by 365,000 on a month-over-month, seasonally adjusted basis.
  • Small business hiring overall did trend negatively in some industries, namely Construction, Wholesale Distribution, Financial Services and Real Estate.

Dorchester Minerals, L.P. Announces Third Quarter Results

Retrieved on: 
Thursday, November 5, 2020

The Partnerships cash distributions are not comparable to its net earnings due to timing and other differences including depletion.

Key Points: 
  • The Partnerships cash distributions are not comparable to its net earnings due to timing and other differences including depletion.
  • Dorchester Minerals, L.P. is a Dallas based owner of producing and non-producing oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests located in 27 states.
  • Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected.
  • These and other factors are set forth in the Partnership's filings with the Securities and Exchange Commission.